Your browser doesn't support javascript.
loading
iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation.
Tristán-Noguero, Alba; Fernández-Carasa, Irene; Calatayud, Carles; Bermejo-Casadesús, Cristina; Pons-Espinal, Meritxell; Colini Baldeschi, Arianna; Campa, Leticia; Artigas, Francesc; Bortolozzi, Analia; Domingo-Jiménez, Rosario; Ibáñez, Salvador; Pineda, Mercè; Artuch, Rafael; Raya, Ángel; García-Cazorla, Àngels; Consiglio, Antonella.
Afiliação
  • Tristán-Noguero A; Neurometabolic Unit and Synaptic Metabolism Lab, Neurology Department, Institut Pediàtric de Recerca, Hospital Sant Joan de Déu, Barcelona, Spain.
  • Fernández-Carasa I; Department of Pathology and Experimental Therapeutics, Bellvitge University Hospital-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Calatayud C; Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain.
  • Bermejo-Casadesús C; Department of Pathology and Experimental Therapeutics, Bellvitge University Hospital-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Pons-Espinal M; Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain.
  • Colini Baldeschi A; Regenerative Medicine Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
  • Campa L; Program for Translation of Regenerative Medicine in Catalonia (P-[CMRC]), Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain.
  • Artigas F; Neurometabolic Unit and Synaptic Metabolism Lab, Neurology Department, Institut Pediàtric de Recerca, Hospital Sant Joan de Déu, Barcelona, Spain.
  • Bortolozzi A; Department of Pathology and Experimental Therapeutics, Bellvitge University Hospital-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Domingo-Jiménez R; Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain.
  • Ibáñez S; Department of Pathology and Experimental Therapeutics, Bellvitge University Hospital-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Pineda M; Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain.
  • Artuch R; Institut d'Investigacions Biomèdiques de Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain.
  • Raya Á; Institut d'Investigacions August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • García-Cazorla À; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), ISCIII, Madrid, Spain.
  • Consiglio A; Institut d'Investigacions Biomèdiques de Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain.
EMBO Mol Med ; 15(3): e15847, 2023 03 08.
Article em En | MEDLINE | ID: mdl-36740977
Tyrosine hydroxylase deficiency (THD) is a rare genetic disorder leading to dopaminergic depletion and early-onset Parkinsonism. Affected children present with either a severe form that does not respond to L-Dopa treatment (THD-B) or a milder L-Dopa responsive form (THD-A). We generated induced pluripotent stem cells (iPSCs) from THD patients that were differentiated into dopaminergic neurons (DAn) and compared with control-DAn from healthy individuals and gene-corrected isogenic controls. Consistent with patients, THD iPSC-DAn displayed lower levels of DA metabolites and reduced TH expression, when compared to controls. Moreover, THD iPSC-DAn showed abnormal morphology, including reduced total neurite length and neurite arborization defects, which were not evident in DAn differentiated from control-iPSC. Treatment of THD-iPSC-DAn with L-Dopa rescued the neuronal defects and disease phenotype only in THDA-DAn. Interestingly, L-Dopa treatment at the stage of neuronal precursors could prevent the alterations in THDB-iPSC-DAn, thus suggesting the existence of a critical developmental window in THD. Our iPSC-based model recapitulates THD disease phenotypes and response to treatment, representing a promising tool for investigating pathogenic mechanisms, drug screening, and personalized management.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Levodopa / Células-Tronco Pluripotentes Induzidas Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Levodopa / Células-Tronco Pluripotentes Induzidas Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article